1 / 43

Radioembolization of Liver metastases from Colorectal cancer

No financial Disclosures . Approximately 148,810 Americans are diagnosed with colorectal cancer annually 49,960 die, mostly with metastatic disease 437,000 annual deaths worldwide 60% cases develop liver metastases and in 20% of these, liver represents th

tahmores
Download Presentation

Radioembolization of Liver metastases from Colorectal cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Radioembolization of Liver metastases from Colorectal cancer

    2. No financial Disclosures

    7. Nonsurgical treatment options for patients with liver isolated colorectal cancer metastases who are not candidates for potentially curable resection.

    8. Therasphere

    9. SIR –spheres

    11. Yttrium –90 emits Beta radiation

    13. Candidates for therapy

    14. Contraindications

    15. Pretreatment Mesenteric Angiography

    18. GDA and right gastric arteries should be identified and prophylactically embolized ( esp when embolic SIR –spheres are used )

    21. Pulmonary shunting

    25. Response to Therapy

    29. Complications

    30. 2002, the FDA gave pre-market approval of SIR-Spheres® as a brachytherapy device for the treatment of metastases from colorectal cancer. Phase III randomized clinical trial, 74 patients with liver isolated CRC metastates were randomly assigned HIA chemotherapy with FUDR alone or in conjunction with a single intrahepatic artery administration of SIR-Spheres.

    36. Phase I study of SIR-spheres with systemic FOLFOX N=20

    37. Ongoing Studies

    39. FOXFIRE

    42. Future Directions

    43. Acknowledgements Dr. Nael Saad, M.D

More Related